
Sign up to save your podcasts
Or
In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice.
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
4.6
256256 ratings
In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice.
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
79 Listeners
132 Listeners
488 Listeners
264 Listeners
3,312 Listeners
147 Listeners
90 Listeners
1,295 Listeners
694 Listeners
563 Listeners
446 Listeners
675 Listeners
113 Listeners
131 Listeners
90 Listeners